Magnesium glucoheptonate
ApprovedSmall molecule
Magnesium glucoheptonate is one of 23 small molecule programs targeting Atrial Fibrillation. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Magnesium glucoheptonate
SScarborough General Hospital
Approved
Xylocaine
MMEDRx USA, Inc.
Preclinical
Anticoagulants
SanofiPreclinical
Direct Anticoagulant
BayerPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Statin
Bristol-Myers SquibbPreclinical
Warfarin Sodium
Boehringer IngelheimPreclinical
Magnesium SO4
HHospital de Base
Preclinical
Medication
NNYU Langone Health
Preclinical
Anticoagulation
HHospital Álvaro Cunqueiro
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Magnesium glucoheptonate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SScarborough General Hospital